Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$64.80 USD
-2.02 (-3.02%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $65.00 +0.20 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -526.24 | -388.96 | -215.31 | -127.29 | -121.69 |
Depreciation/Amortization & Depletion | 11.89 | 5.81 | 2.28 | 1.83 | 1.29 |
Net Change from Assets/Liabilities | 3.09 | -24.70 | 8.46 | 89.12 | -0.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 96.93 | 108.33 | 62.06 | 45.29 | 29.83 |
Net Cash From Operating Activities | -414.33 | -299.52 | -142.52 | 8.94 | -90.91 |
Property & Equipment | -1.42 | -11.34 | -48.87 | -11.05 | -2.62 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 240.67 | -250.80 | -98.91 | -185.46 | -72.09 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 239.25 | -262.13 | -147.78 | -196.52 | -74.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 182.69 | 17.54 | 296.91 | 188.88 | 36.21 |
Issuance (Repayment) of Debt | -0.86 | 334.66 | 0.00 | 0.00 | 135.57 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 39.48 | 163.96 | 23.08 | 45.24 | -11.99 |
Net Cash from Financing Activities | 221.32 | 516.17 | 319.98 | 234.12 | 159.79 |
Effect of Exchange Rate Changes | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 46.22 | -45.48 | 29.68 | 46.55 | -5.82 |
Cash at Beginning of Period | 67.18 | 112.67 | 82.99 | 36.43 | 42.26 |
Cash at End of Period | 113.40 | 67.18 | 112.67 | 82.99 | 36.43 |
Diluted Net EPS | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 |
Fiscal Year End for Cytokinetics, Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -526.24 | -389.35 | -259.93 | -131.29 |
Depreciation/Amortization & Depletion | NA | 11.89 | 5.56 | 3.70 | 1.85 |
Net Change from Assets/Liabilities | NA | 3.09 | -41.79 | -43.27 | -19.17 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 96.93 | 85.29 | 55.40 | 26.33 |
Net Cash From Operating Activities | NA | -414.33 | -340.30 | -244.09 | -122.29 |
Property & Equipment | NA | -1.42 | -1.34 | -1.12 | -0.40 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 240.67 | 322.00 | 248.74 | 165.90 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 239.25 | 320.66 | 247.63 | 165.50 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 182.69 | 0.00 | 9.23 | 3.55 |
Issuance (Repayment) of Debt | NA | -0.86 | -0.64 | -0.42 | -0.21 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 39.48 | 53.15 | -10.52 | -10.52 |
Net Cash from Financing Activities | NA | 221.32 | 52.52 | -1.70 | -7.18 |
Effect of Exchange Rate Changes | NA | -0.02 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 46.22 | 32.89 | 1.83 | 36.03 |
Cash at Beginning of Period | NA | 67.18 | 67.18 | 67.18 | 67.18 |
Cash at End of Period | NA | 113.40 | 100.07 | 69.01 | 103.22 |
Diluted Net EPS | NA | -1.38 | -1.35 | -1.34 | -1.38 |